Sotera Health Company Common Stock vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Sotera Health Company Common Stock trades at $17.68 (market cap $5.20B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.92 (market cap $2.51B). The key difference: Sotera Health Company Common Stock is far larger — about 2.1× SELLAS Life Sciences Group Inc. Common Stock's market cap, and SELLAS Life Sciences Group Inc. Common Stock is more actively traded (6,359,048 versus 1,647,777). Which is the better fit depends on your goals — on Pluang, investors hold Sotera Health Company Common Stock for 0 Days and SELLAS Life Sciences Group Inc. Common Stock for 0 Days on average.
| SHC | SLS | |
|---|---|---|
Market Cap | $5.20B | $2.51B |
Volume | 1,647,777 | 6,359,048 |
Sector | Health | Health |
52-Week High | $19.57 | $15.46 |
52-Week Low | $13.13 | $1.39 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $7.11B | $2.37B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SELLAS Life Sciences (SLS) trades at $12.41, up 4.02% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported no revenue in 2025, with a net loss of $26.86 million, negative ROE and ROA, and a high P/B ratio of 18.2. Recent news includes a law firm investigation into investor claims and positive preclinical data for SLS009 in pancreatic cancer models presented at the AACR conference.
The outlook hinges on upcoming clinical trial results, particularly the Phase 3 REGAL trial for GPS in AML, with topline data expected in Q4 2026. While analyst consensus is unanimously bullish, significant risks include the binary nature of trial outcomes, ongoing legal scrutiny, and persistent negative profitability metrics. The stock's recent surge of ~300% year-to-date reflects high investor optimism but also heightened volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Sotera Health Company is a US provider of sterilization and lab testing services for the healthcare industry, operating through its Sterigenics, Nordion, and Nelson Labs businesses.
Read more on SHC →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →